IP Library Granted Patent US 10,149,857
Granted Patent B2
US 10,149,857 · App. 15/454,420 · Granted Dec 11, 2018

Lyophilized cyclophosphamide composition and methods of preparation thereof

Inventors: Andrew M. Smith (Philadelphia, PA); Timothy S. Dutill (Plymouth Meeting, PA); Edward H. Trappler (Langhorne, PA)
Assignee: AMPAC Fine Chemicals LLC
A61K31/661A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,149,857
App. No.
15/454,420
Granted
Dec 11, 2018
Kind
B2
Abstract

An improved lyophilized cyclophosphamide solid composition is described. The lyophilized cyclophosphamide solid composition is thermally stable, contains anhydrous cyclophosphamide and mannitol, and is substantially free of cyclophosphamide monohydrate. A method for preparing the lyophilized cyclophosphamide solid composition is also provided.

Claims (9)

1. A lyophilized cyclophosphamide solid composition comprising cyclophosphamide and mannitol, wherein the composition contains one or more crystalline forms exhibiting an X-ray powder diffraction (XRPD) spectrum having a peak at diffraction angle (2θ) of 8.5±0.2, and the composition has a moisture content of less than 2% by weight.

2. The lyophilized cyclophosphamide solid composition of claim 1 having a moisture content of less than 1% by weight.

3. The lyophilized cyclophosphamide solid composition of claim 1 , wherein there is no evidence of cyclophosphamide monohydrate in the XRPD spectrum.

4. The lyophilized cyclophosphamide solid composition of claim 1 , containing cyclophosphamide anhydrous enantiopure form and δ D-mannitol.

5. A lyophilized cyclophosphamide solid composition consisting essentially of cyclophosphamide and mannitol, wherein the composition contains one or more crystalline forms having an X-ray powder diffraction (XRPD) spectrum comprising a peak at diffraction angle (2θ) of 8.5±0.2°, and the composition has a moisture content of less than 2% by weight.

6. The lyophilized cyclophosphamide solid composition of claim 5 , wherein there is no evidence of cyclophosphamide monohydrate in the XRPD spectrum.

7. The lyophilized cyclophosphamide solid composition of claim 6 , having a weight ratio of mannitol to cyclophoshamide anhydrous of 1.2 to 1.8.

8. The lyophilized cyclophosphamide solid composition of claim 1 , wherein the XRPD spectrum further comprises peaks at diffraction angle (2θ) of 8.1±0.2°, 12.3±0.2°, and 13.4±0.2°.

9. The lyophilized cyclophosphamide solid composition of claim 5 having a moisture content of less than 1% by weight.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2017
From: SMITH, ANDREW M.; DUTILL, TIMOTHY S.; TRAPPLER, EDWARD H.
To: LYOPHILIZATION TECHNOLOGY, INC.
Reel/Frame 041967/0425 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2017
From: LYOPHILIZATION TECHNOLOGY, INC.
To: AMPAC FINE CHEMICALS LLC
Reel/Frame 041967/0637 →
Continuity (1)
Related Publication 20180256608A1 · Sep 13, 2018
Cited By (2)
US 12,433,905 US 12,453,737